CureVac Shareholders Face Critical Deadline in BioNTech Takeover

The independent existence of CureVac as a publicly traded company is drawing to a close. Following decisive shareholder approval, the acquisition by its Mainz-based competitor BioNTech is proceeding, placing investors at a pivotal crossroads. With key deadlines approaching within days, shareholders who delay action risk being caught in the complex mechanics of the takeover process.

During an extraordinary general meeting held this past Tuesday, shareholders expressed near-unanimous support for the transaction. An impressive 99.16% of votes cast were in favor of BioNTech’s public share exchange offer. This resounding endorsement signals that investors see limited prospects for the Tübingen-based company operating independently and prefer its future secured under the larger partner’s Read more...